Venturs and Momenta Shares Crater on Negative News Print E-mail
By Staff and Wire Reports   
Monday, 25 June 2012 19:53
Below is a look at some of the headlines for companies that made news in the healthcare sector on June 25, 2012.

Ventrus Biosciences (NASDAQ:VTUS) shares lose more than half their value, following word that the firm’s iferanserin drug for hemorrhoidal disease could not meet the primary end points of a phase 3 trial, the elimination of bleeding, itching and pain. The company will abandon the treatment, and will concentrate on its other compounds in its place.
Momenta Pharmaceuticals (NASDAQ:MNTA) craters Monday following an unfavorable ruling over the weekend in patent litigation brought by Teva (NASDAQ:TEVA), over the drug Copaxone. However, Oppenheimer is confident as to the stock’s long-term value, looking past the current near-term setback.

Also Monday:

Baxter International Inc. (NYSE:BAX) today announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] as a treatment for multifocal motor neuropathy (MMN).

Bristol-Myers Squibb Company (NYSE: BMY)
and Pfizer (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for ELIQUIS® (apixaban) for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

Cannabis Science Inc (OTCBB: CBIS)
announced the appointment of Mariel Selbovitz, MPH as Vice President of Research Program Development, reflecting the maturing direction of the company with the initiation of the CS-TATI-1 Program and related pandemic drug resistant infectious diseases and co-morbidities research programs to enhance the Company’s scope of expertise on the development of novel phytocannabinoid-based therapeutics, including those for HIV oncology and SAEs of chemotherapy.

China Biologic Products, Inc. (NASDAQ: CBPO)
, a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its indirectly owned subsidiary, Shandong Taibang Biological Products Co., Ltd. ("Taibang") has received a manufacturing approval certificate from the China State Food and Drug Administration ("SFDA") for Human Coagulation Factor VIII ("FVIII").

Compugen Ltd. (NASDAQ: CGEN)
and Merck Serono, a division of Merck, Darmstadt, Germany, today announced the establishment of Neviah Genomics, a novel start-up company focused on the discovery and development of novel biomarkers for the prediction of drug-induced toxicity.

Covidien plc (NYSE: COV)
will report third-quarter results on July 26, 2012, before trading begins.

CytRx Corporation (NASDAQ: CYTR)
, a biopharmaceutical company specializing in oncology, today announced the recommendation by the Data Safety Monitoring Board (DSMB) to continue with the global Phase 2b clinical trial with tamibarotene in combination with chemotherapeutical agents as a first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC).

Demandware®, Inc. (NYSE: DWRE), a leader in on-demand ecommerce, today announced that London Drugs, a popular chain of Canadian retail stores serving more than 45 million customers each year, has selected Demandware to power its digital commerce strategy, starting with the relaunch of its Canadian ecommerce site.

Derma Sciences, Inc. (Nasdaq: DSCI)
, a medical device and pharmaceutical company focused on advanced wound care, today announced that its stock has been added the Russell 3000® Index.

EnteroMedics Inc. (NASDAQ: ETRM)
, the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that it has been added to the Russell 3000®and Russell 2000® Indexes.

GeneThera Inc. (OTCQB: GTHR)
is pleased to announce that Applied Genetics, GeneThera's majority owned subsidiary, has initiated commercial operation of its molecular diagnostic laboratory based in Monterrey, Mexico.

GTx, Inc. (Nasdaq: GTXI)
announced today that in a Phase IIb clinical study of enobosarm, there was significantly improved physical function after 16 weeks of treatment, compared to placebo, in both hypogonadal (low testosterone) and eugonadal (normal testosterone) subjects.

InspireMD, Inc. (OTCBB: NSPR)
, a medical device company focusing on the development and commercialization of its proprietary stent platform technology for use in patients with Acute Myocardial Infarctions, today announced that management will present at the Harvard Investors Group meeting in New York on Wednesday, June 27.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX)
, announced today that LX4211, an investigational, oral, dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2), showed substantial, dose-dependent, statistically-significant reductions in hemoglobin A1c (HbA1c) in a Phase 2b trial in patients diagnosed with poorly-controlled type 2 diabetes who were concurrently treated with metformin, an established diabetes therapy.

Medidata Solutions (NASDAQ: MDSO)
will showcase new products and features that broaden its clinical cloud platform at the upcoming Drug Information Association’s (DIA) Annual Meeting, June 24-28 in Philadelphia, Pa.

Contract research organization (CRO) LSK Global PS has strengthened its partnership with Medidata Solutions (NASDAQ: MDSO) by becoming the first Korean partner to attain accreditation in the Medidata Partner Program.

MRI Interventions, Inc. (OTCBB:MRIC)
and Brainlab AG today announced an alliance with Tocagen Inc. in the fight against the most aggressive form of brain cancer, recurrent high grade gliomas including glioblastoma multiforme (GBM).

NanoViricides, Inc. (OTC BB: NNVC)
(the "Company") announced today that Mr. Stanley Glick, CPA has been appointed as a Director of the Company and the Chairman of its Audit Committee.

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP)
, a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, announced today that new findings from the double-blind, placebo-controlled Phase 3 REPLACE study of Natpara™ (recombinant human parathyroid hormone (rhPTH [1-84])) support the drug’s therapeutic potential as the first parathyroid hormone replacement therapy for adults with hypoparathyroidism.

Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO)
, a specialty pharmaceutical company with a focus on cardiovascular health, is pleased to announce it has entered into a subscription agreement with a US Institutional Fund; Crossover Healthcare Fund LLC, an Affiliate of Summer Street Research Partners, and intends to close a non-brokered private placement for CDN $5 million.

Repligen Corporation (NASDAQ:RGEN)
today announced that the Company’s stock has been added to the Russell 2000® index, a subset of the Russell 3000® and the Russell Global® indexes.

Simulations Plus, Inc. (Nasdaq: SLP)
, a leading provider of simulation and modeling software for pharmaceutical discovery and development, announced today that it has signed a collaboration agreement with a top-5 pharmaceutical company to add a transdermal and subcutaneous dosing model within its industry gold standard GastroPlus™ simulation software program.

Sinovac Biotech Ltd. (Nasdaq: SVA)
, a leading provider of biopharmaceutical products in China, today provided an update on its Phase III clinical trial progress and commercialization preparation for its proprietary inactivated Enterovirus 71 (EV71) vaccine against hand, foot and mouth disease (HFMD).

is pleased to report that an abstract prepared by Stellar scientists on KLH immunobiology has been accepted for presentation at the prestigious ImVacS 2012 Conference (The Immunotherapeutics & Vaccine Summit) August 13-16, 2012 in Cambridge, MA - ( in a poster presentation titled "Keyhole Limpet Hemocyanin (KLH): A Unique, Unlikely Pharmaceutical Product."

Teleflex Incorporated (NYSE:TFX)
, a leading global provider of medical devices for critical care and surgery, announced it has acquired Semprus BioSciences (Cambridge, Massachusetts), a biomedical company and spin out from Massachusetts Institute of Technology (MIT).

Trovagene, Inc. (Nasdaq:  TROV)
, a developer of trans-renal molecular diagnostics, announced that Russell Investments has added Trovagene to the Russell Microcap Index based on Russell Investments annual reconstitution of its family of U.S. indexes finalized after the close of the U.S. markets on June 22, 2012.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus